Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction

Congestive Heart Failure

Volumn 19, Issue 4, 2013, Pages

  Nosaka, Kazumasa ^a,b   Nakamura, Kazufumi ^a   Kusano, Kengo ^a   Toh, Norihisa ^a   Tada, Takeshi ^a   Miyoshi, Toru ^a   Doi, Masayuki ^b   Kohno, Kunihisa ^a   Morita, Hiroshi ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ADULT; ARTICLE; BLOOD LEVEL; CARDIAC PATIENT; CARDIOMYOPATHY; COMPARATIVE STUDY; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; VALVULAR HEART DISEASE;

BIOLOGICAL MARKERS; CYSTATIN C; DIASTOLE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84881277214     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/chf.12039     Document Type: Article

References (21)

1. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510-1518.
2. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.
3. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol. 2001;88:530-533.
4. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269.
5. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
6. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol. 2006;47:1-8.
7. Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31:703-711.
8. Narvaez-Sanchez R, Gonzalez L, Salamanca A, et al. Cystatin C could be a replacement to serum creatinine for diagnosing and monitoring kidney function in children. Clin Biochem. 2008;41: 498-503.
9. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707.
10. Tan GD, Lewis AV, James TJ, et al. Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care. 2002;25:2004-2009.
11. Moran A, Katz R, Smith NL, et al. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail. 2008;14: 19-26.
12. Ix JH, Shlipak MG, Chertow GM, et al. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail. 2006;12:601-607.
13. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
14. Toh N, Morita H, Nagase S, et al. Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography. Heart Rhythm. 2010;7:218-224.
15. Fricker M, Wiesli P, Brandle M, et al. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63:1944-1947.
16. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003;338:87-90.
17. Cheng XW, Obata K, Kuzuya M, et al. Elastolytic cathepsin induction/activation system exists in myocardium. Hypertension. 2006;48:979-987.
18. Tang WH, Van Lente F, Shrestha K, et al. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail. 2008;14:394-399.
19. Nejat M, Pickering JW, Devarajan P, et al. Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int. 2012;81:1254-1262.
20. Evangelopoulos AA, Vallianou NG, Bountziouka VP, et al. The Impact of Demographic Characteristics and Lifestyle in the Distribution of Cystatin C Values in a Healthy Greek Adult Population. Cardiol Res Pract. 2011:163281. doi: 10.4061/2011/163281.
21. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cyctatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416-1421.